EMA Medicine safety communications
Abecma / Breyanzi / Carvykti / Kymriah / Tecartus / Yescarta: adverse event
Published by European Medicines Agency:
Summary
Adverse event
Medicine
Abecma / Breyanzi / Carvykti / Kymriah / Tecartus / Yescarta
- Category
- Medicine safety communications
- Product type
- Human medicine
- Active substance(s): idecabtagene vicleucel;lisocabtagene maraleucel;tisagenlecleucel;brexucabtagene autoleucel;axicabtagene ciloleucel;ciltacabtagene autoleucel
- Therapeutic area: Multiple Myeloma;Lymphoma, Large B-Cell, Diffuse;Lymphoma, Follicular;Mediastinal Neoplasms;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Lymphoma, Mantle-Cell
- ATC code: L01;L01XL05;L01XL04;L01X;L01XX70
Measures and alternatives
- Regulatory outcome: Variation
Source: EMA — medicine safety communications — European Medicines Agency
Source: European Medicines Agency (EMA). Reproduced with acknowledgement of the source, in line with the EMA legal notice. EU Safety Radar is an independent information service; the text above presents the official data in the original language — the notice published by the authority is authoritative.
Open the original notice (www.ema.europa.eu) ↗